Evidence map›Paper›PMID 36905763›Full record

ReviewCurrent opinion in chemical biology2023

Anti-glycan monoclonal antibodies: Basic research and clinical applications.

Kara M Gillmann, J Sebastian Temme, Samantha Marglous, Claire E Brown, Jeffrey C Gildersleeve

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. The Role of Glycans in Human Immunity-A Sweet Code.Molecules (Basel, Switzerland) · 2025
    Review
  7. Defined Glycan Ligands for Detecting Rare l-Sugar-Binding Proteins.Journal of the American Chemical Society · 2025
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Chemical biology tools to probe bacterial glycans.Current opinion in chemical biology · 2024
    Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kara M GillmannChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA.
J Sebastian TemmeChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA.
Samantha MarglousChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA.
Claire E BrownChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA.
Jeffrey C GildersleeveChemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702, USA. Electronic address: gildersj@mail.nih.gov.
National Cancer Institute · USFrederick National Laboratory for Cancer Research · US

Funding

Carbohydrate Microarray Profiling of Glycan-Binding Antibodies and LectinsZIABC010740 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GILDERSLEEVE, JEFFREY · 2009 to 2025
$10.7M
Intramural NIH HHS ZIA BC010740
6 · The paper itself

Abstract

Anti-glycan monoclonal antibodies have important applications in human health and basic research. Therapeutic antibodies that recognize cancer- or pathogen-associated glycans have been investigated in numerous clinical trials, resulting in two FDA-approved biopharmaceuticals. Anti-glycan antibodies are also utilized to diagnose, prognosticate, and monitor disease progression, as well as to study the biological roles and expression of glycans. High-quality anti-glycan mAbs are still in limited supply, highlighting the need for new technologies for anti-glycan antibody discovery. This review discusses anti-glycan monoclonal antibodies with applications to basic research, diagnostics, and therapeutics, focusing on recent advances in mAbs targeting cancer- and infectious disease-associated glycans.

Indexed as

Antibodies, MonoclonalNeoplasmsHumansPolysaccharidesAntibodies, MonoclonalPolysaccharidesAnti-Glycan monoclonal antibodyCancer therapyDiagnosticsGlycan-binding antibodyInfectious disease therapyMonoclonal antibody

Identifiers

PMID36905763
PMCPMC10732169
OpenAlexW4323662675

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.